medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2015, Number 1

<< Back Next >>

Rev Esp Med Quir 2015; 20 (1)

Aurora A kinase as biomarker and possible therapeutic target in breast cancer

Miranda-Aguirre AP, Suárez-Cuenca JA, Erazo-Valle Solís AA

Language: Spanish
References: 22
Page: 60-66
PDF size: 452.77 Kb.


ABSTRACT

Breast cancer is a health problem in the world and represents one of the most diagnosed neoplasms in the world. There are multiple factors associated with the prognosis of patients with this cancer. These factors are clinical and pathological. Recently, a family of threonine-serine kinases called Auroras have been described. Aurora A, B and C were discovered in mammals. Aurora A has reached importance as it has been found overexpressed in many solid tumors such as cancer is breast, ovary, pancreas, bladder, colorectal, gastric and esophageal. This kinase has shown to participate in the effective and precise separation of the mitotic spindle through regulation of the chromosome centrosomes. Aurora A has been associated with tumoral genesis and progression. Its role has been studied as prognostic and early diagnostic tool, either its overexpression as well as its intracellular localization. This has led to the development of new molecules directed to selectively inhibit Aurora, resulting in inhibition of growth in immortalized cell lines. The aim of this paper is to give a comprehensive overview of the importance of this new family of kinases.


REFERENCES

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Disponible en: http://globocan.iarc.fr

  2. INEGI. Estadísticas a propósito del Día Internacional contra el Cáncer de Mama. Instituto Nacional de Estadística y Geografía. Disponible en: http://www.inegi.org.mx/inegi/contenidos/ espanol/prensa/Contenidos/estadisticas/2013/ mama0.pdf. Consultado el 5/12/2014

  3. Disponible en http://www.inegi.org.mx/sistemas/sisept/ Default.aspx?t=mdemo125&s=est&c=23589

  4. Pruefer FG, Unger-Saldana K, Mohamier L, et al. Tumor HGF lacks prognostic significance in Mexican breast cancer patients. J Exp Clin Cancer Res 2006;25(3):357-364.

  5. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-752.

  6. Rodriguez-Cuevas SA, Luna-Arias JP. Impact of genomic signatures in the therapeutic decision of breast cancer. Cir Cir 2007;75(6):415-417.

  7. de Ronde JJ, Hannemann J, Halfwerk H, et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 2010;119(1):119-126.

  8. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer. Dec 2004;4(12):927-936.

  9. Vidarsdottir L, Bodvarsdottir SK, Hilmarsdottir H, Tryggvadottir L, Eyfjord JE. Breast cancer risk associated with AURKA 91T. A polymorphism in relation to BRCA mutations. Cancer Lett 2007;250(2):206-212.

  10. Saeki T, Ouchi M, Ouchi T. Physiological and oncogenic Aurora-A pathway. Int J Biol Sci 2009;5(7):758-762.

  11. Taga M, Hirooka E, Ouchi T. Essential roles of mTOR/Akt pathway in Aurora-A cell transformation. Int J Biol Sci 2009;5(5):444-450.

  12. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003;22(4):451-464.

  13. Eyers PA, Erikson E, Chen LG, Maller JL. A novel mechanism for activation of the protein kinase Aurora A. Curr Biol 2003;13(8):691-697. 66 Revista de Especialidades Médico-Quirúrgicas Volumen 20, Núm. 1, enero-marzo 2015

  14. Warner SL, Bearss DJ, Han H, Von Hoff DD. Targeting Aurora- 2 kinase in cancer. Mol Cancer Ther 2003;2(6):589-595.

  15. Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya PS, Lepsik M, Hajduch M. Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs 2012;30(6):2411-2432.

  16. Wang X, Zhou YX, Qiao W, et al. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 2006;25(54):7148-7158.

  17. Xia LP, Zhou FF, Yang MT, Liu Q. Roles of Aurora-A in tumorigenesis and prognosis of breast cancer. Ai Zheng 2009;28(6):668-672.

  18. Guttilla IK, Adams BD, White BA. ERalpha, microRNAs, and the epithelial-mesenchymal transition in breast cancer. Trends Endocrinol Metab 2012;23(2):73-82.

  19. D’Assoro AB, Liu T, Quatraro C, et al. The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERalpha(+) breast cancer cells. Oncogene 2014;33(5):599-610.

  20. Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y. Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res 2008;14(14):4455- 4462.

  21. Siggelkow W, Boehm D, Gebhard S, et al. Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients. BMC Cancer 2012;12:562.

  22. Ferchichi I, Sassi Hannachi S, Baccar A, et al. Assessment of Aurora A kinase expression in breast cancer: a tool for early diagnosis? Dis Markers 2013;34(2):63-69.




2020     |     www.medigraphic.com